NCT00387465View on ClinicalTrials.gov

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2014

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Azacitidine 30mg/m2

Azacitidine 30mg/m2 subcutaneously (SQ)

DRUG

Entinostat

7mg by mouth (PO) on days 3 and 10 of each cycle

DRUG

Azacitidine 40mg/m2

Azacitidine 40mg/m2 SQ

Trial Locations (5)

21224

Johns Hopkins Bayview Medical Center, Baltimore

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore

90033

USC Norris Comprehensive Cancer Center, Los Angeles

92121

Sidney Kimmel Cancer Center, San Diego

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00387465 - Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter